Treatment of five or more brain metastases with stereotactic radiosurgery.
OBJECTIVE
To examine the outcomes of patients with five or more brain metastases treated in a single session with stereotactic radiosurgery (SRS).


METHODS
Sixty-four patients with brain metastases treated with SRS to five or more lesions in a single session were reviewed. Primary disease type, number of lesions, Karnofsky performance score (KPS) at SRS, and status of primary and systemic disease at SRS were included. Patients were treated using dosing as defined by Radiation Therapy Oncology Group Protocol 90-05, with adjustments for critical structures. We defined prior whole-brain radiotherapy (WBRT) as WBRT completed >1 month before SRS and concurrent WBRT as WBRT completed within 1 month before or after SRS. Kaplan-Meier estimates and Cox proportional hazard regression were used to determine which patient and treatment factors predicted overall survival (OS).


RESULTS
The median OS after SRS was 7.5 months. The median KPS was 80 (range, 60-100). A KPS of ≥ 80 significantly influenced OS (median OS, 4.8 months for KPS ≤ 70 vs. 8.8 months for KPS ≥ 80, p = 0.0097). The number of lesions treated did not significantly influence OS (median OS, 6.6 months for eight or fewer lesions vs. 9.9 months for more than eight, p = nonsignificant). Primary site histology did not significantly influence median OS. On multivariate Cox modeling, KPS and prior WBRT significantly predicted for OS. Whole-brain radiotherapy before SRS compared with concurrent WBRT significantly influenced survival, with a risk ratio of 0.423 (95% confidence interval 0.191-0.936, p = 0.0338). No significant differences were observed when no WBRT was compared with concurrent WBRT or when the no WBRT group was compared with prior WBRT. A KPS of ≤ 70 predicted for poorer outcomes, with a risk ratio of 2.164 (95% confidence interval 1.157-4.049, p = 0.0157).


CONCLUSIONS
Stereotactic radiosurgery to five or more brain lesions is an effective treatment option for patients with metastatic cancer, especially for patients previously treated with WBRT. A KPS of ≥ 80 predicts for an improved outcome.
Department of Radiation Oncology, Cleveland Clinic, Cleveland, OH, USA.
Grant K
GK
Hunter
John H
JH
Suh
Alwyn M
AM
Reuther
Michael A
MA
Vogelbaum
Gene H
GH
Barnett
Lilyana
L
Angelov
Robert J
RJ
Weil
Gennady
G
Neyman
Samuel T
ST
Chao
D001932:Brain Neoplasms / Q000401:mortality / Q000532:radiotherapy / Q000556:secondary* / Q000601:surgery*; D016001:Confidence Intervals; D016371:Cranial Irradiation / Q000379:methods / Q000401:mortality; D005260:Female; D006801:Humans; D017567:Karnofsky Performance Status; D008297:Male; D008875:Middle Aged; D016634:Radiosurgery / Q000401:mortality; D012044:Regression Analysis; D016896:Treatment Outcome; D047368:Tumor Burden